Pharming milks cost benefits through Chinese alliance
This article was originally published in Scrip
The flow of alliances between Chinese firms and Western partners involving technology and novel products continues, with Dutch firm Pharming the latest to enter into a broad partnership aimed at the cost-effective, high-quality manufacture of biologics in its portfolio and the commercialization of its lead product in China.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.